Philippe Picaut News Today

IND opened and Fast Track Designation granted by FDA for Erythromelalgia First patients enrolled in ACT study in Chemotherapy-Induced Peripheral Neuropathy European biotech AlgoTx, a clinical

AlgoTx, a biotechnology company dedicated to developing treatments for complex pain, announced today the initiation of its Phase 2 global clinical trial in Chemotherapy-Induced Peripheral Neuropathy

European biotech AlgoTx, an innovator in complex pain therapy, today announces the U.S. Food and Drug Administration (FDA) cleared its Investigational New Drug Application (IND) for Phase 2 candidate